SCYNEXIS(FRA) 135

Market Cap€46.76M

Since IPON/A

5 YearN/A

1 YearN/A

1 MonthN/A

€4.50

-1.75%

-0.08Today

SCYNEXIS Financials at a Glance

Market Cap

€46.76M

Revenue (TTM)

€16.51

Net Income (TTM)

-€8.66

EPS (TTM)

-€1.56

P/E Ratio

-3.01

Dividend

€0.00

Beta (Volatility)

0.08 (Low)

Dividend

€0.00

Beta (Volatility)

0.08 (Low)

Price

€4.50

Volume

Open

€4.51

Price

€4.50

Volume

Open

€4.51

Previous Close

€4.50

Daily Range

€4.50 - €4.55

52-Week Range

€3.93 - €7.86

Estimated Earnings Date

N/A

Dividend

€0.00

Beta (Volatility)

0.08 (Low)

Price

€4.50

Volume

Open

€4.51

Previous Close

€4.50

Daily Range

€4.50 - €4.55

52-Week Range

€3.93 - €7.86

Estimated Earnings Date

N/A

135 News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About SCYNEXIS

SCYNEXIS, Inc. is a biotechnology company, which engages in the development of novel oral and intravenous triterpenoid antifungal for the treatment of several serious fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. The company was founded by Scot Kevin Huber, Terry Eugene Marquardt, Pierre Bernard Jacques Monnet, Russell J. Outcalt, and Yves Joseph Ribeill on November 4, 1999 and is headquartered in Jersey City, NJ.

Industry

Pharmaceuticals

Sector

Health Care

Employees

CEO

David Angulo Gonzalez, MD

Website

www.scynexis.com

135 Financials

Key Financial Metrics (TTM)

Gross Margin

N/A

Operating Margin

N/A

Net Income Margin

N/A

Return on Equity

-17.97%

Return on Capital

N/A

Return on Assets

N/A

Earnings Yield

-33.22%

Dividend Yield

0.00%

Payout Ratio

N/A

Stock Overview

Market Cap

€46.76M

Shares Outstanding

9.95M

Volume

Avg. Volume

Financials (TTM)

Gross Profit

N/A

Operating Income

N/A

EBITDA

N/A

Operating Cash Flow

N/A

Capital Expenditure

N/A

Free Cash Flow

N/A

Cash & ST Invst.

N/A

Total Debt

N/A

SCYNEXIS Performance Analysis

SCYNEXIS annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2022	2022-12-31	EUR 4,844,077	-56.5%
2023	2023-12-31	EUR 129,626,286	2576.0%
2024	2024-12-31	EUR 3,463,097	-97.3%
2025	2025-12-31	EUR 18,253,945	427.1%

SCYNEXIS annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2022	2022-12-31	EUR -11.22	33.1%
2023	2023-12-31	EUR 10.25	N/A
2024	2024-12-31	EUR -3.25	N/A
2025	2025-12-31	EUR -1.22	-62.3%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q2 2026YOY CHG

Revenue

€0.20

+0.2%

Gross Profit

€0.00

N/A

Gross Margin

N/A

Market Cap

€46.76M

N/A

Market Cap/Employee

€2.48

N/A

Employees

N/A

Net Income

€6.36

-1.0%

EBITDA

-€6.69

+0.8%

Quarterly Fundamentals

Name

Q2 2026YOY CHG

Total Cash

€10.94

-5.2%

Total Debt

€1.70

+0.8%

Accounts Receivable

€0.00

+0.0%

Inventory

€0.00

N/A

Long Term Debt

€1.24

+0.7%

Short Term Debt

€0.46

+1.2%

Return on Assets

-14.77%

+0.6%

Return on Invested Capital

-27.21%

N/A

Free Cash Flow

-€12.84

+2.1%

Operating Cash Flow

-€12.84

+2.1%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

^GSPCS&P 500

^GSPCS&P 500$7,684.24-0.00%

^DJIDJI

^DJIDJI$53,254.61-0.01%

^IXICNASDAQ

^IXICNASDAQ$26,319.55-0.00%

BTCBitcoin

BTCBitcoin$78,890.00-0.00%

SPCXSPCX

SPCXSPCX$142.81+0.01%

AAPLAAPL

AAPLAAPL$315.25-0.01%

AMZNAMZN

AMZNAMZN$258.45-0.03%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

PCGPG&E

PCGPG&E$13.27-0.20%

NVDANvidia

NVDANvidia$220.78+0.01%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF$9.97+0.11%

CNHCNH Industrial

CNHCNH Industrial$11.83+0.01%

NUNu Holdings

NUNu Holdings$14.55+0.02%

BITOProShares Trust - ProShares Bitcoin ETF

BITOProShares Trust - ProShares Bitcoin ETF$10.63+0.02%

AALAmerican Airlines Group

AALAmerican Airlines Group$13.43-0.02%

Questions About 135

What is the current price of SCYNEXIS?

SCYNEXIS is trading at €4.50 per share.

What is the 52-week range for SCYNEXIS?

Over the past 52 weeks, SCYNEXIS has traded between €3.93 and €7.86.

How much debt does SCYNEXIS have?

As of the most recent reporting period, SCYNEXIS reported total debt of €1.70M.

How much cash does SCYNEXIS have on hand?

SCYNEXIS reported €9.24M in cash and cash equivalents in its most recent financial results.

What is SCYNEXIS’s dividend yield?

SCYNEXIS does not currently have a dividend yield.

SCYNEXIS(FRA) 135

SCYNEXIS Financials at a Glance

135 News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About SCYNEXIS

135 Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

SCYNEXIS Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About 135

What is the current price of SCYNEXIS?

What is the 52-week range for SCYNEXIS?

How much debt does SCYNEXIS have?

How much cash does SCYNEXIS have on hand?

What is SCYNEXIS’s dividend yield?

Premium Investing Services